Biotricity Reports Strong Start To Fiscal Year 2024; Company Estimates Q1-FY24 Revenue To Grow YoY By Over 40%
Portfolio Pulse from Happy Mohamed
Biotricity Inc. (NASDAQ:BTCY) has reported a strong start to its Fiscal Year 2024, with an estimated Q1-FY24 revenue growth of over 40% YoY. The company attributes this growth to recurring technology fees and customer second-device sales. The company's Biocare app has had over 10,000 downloads since its launch in January, and its second product, Biotres, is rapidly gaining traction in the industry.
July 06, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biotricity Inc. expects a significant increase in Q1-FY24 revenue, driven by recurring technology fees and sales of its products. This positive financial performance is likely to boost investor confidence and could lead to a short-term increase in the company's stock price.
The company's strong revenue growth estimate for Q1-FY24 indicates a positive financial performance. This, coupled with the success of its products, is likely to boost investor confidence and could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100